Sdi Share Discussion Threads

[netcurtains] 24/1/2017 08:37

right technology at the right time.

[rhomboid] 24/1/2017 08:33

Hi PJ , I reckon they're just somewhat amazed that the NHS is persisting with proven inferior methods of sterilising surgical instruments, it reminds me of the scandal over blood transfusions where everyone knew there was an issue but some health authorities dragged their feet.

[basem1] 24/1/2017 08:29

Am I right in thinking that the 1.7p eps figure does not include any contribution from Astles which should add a further 0.5p eps to the 1.7p figure giving 2.2p ? My valuation here for now is 27/28p, giving an approx pe of 12 plus the cash on the balance sheet. And certainly plenty of room to grow those numbers.

[pj 1] 24/1/2017 08:26

It almost feels as if they are trying to keep ProReveal expectations low, hence, increasing chances of beating/ upgrades?

[rivaldo] 24/1/2017 08:23

Very solid interim results. With an interim PBT of £421,000 SDI are now a sizeable entity. They have cash in the bank, and the outlook for the year is "strong", with the likelihood of more acquisitions.

I note that Finncap have left forecasts unchanged at 1.7p EPS "despite the product mix benefits to gross margin reported in these interim results", which suggests some upside to forecasts later in the year.

With "increased interest in ProReveal" in the UK following the new guidelines and sales in the USA there's an opportunity for a decent boost to turnover and profits from this product.

The Chairman's comments are very positive:

"Ken Ford, Chairman of SDI, commented:

"It has been a positive performance in the first half of the year, and the outlook for the full year is strong. SDI now has a growing portfolio of profitable businesses which are providing the Group with increased and sustained profitability. We have been particularly pleased with the performance of Sentek, the manufacturer of electrochemical sensors that we acquired in October 2015, and we will continue to grow as we seek to diversify our existing product range and widen our addressable market.'"

[noble3r] 24/1/2017 07:56

Very pleased, increased growth and profitability. Extremely excited for full yr results which will include recent acquisition of Astles.

UK market still not adopted ProReveal - can't be long. Currently, it is the only available CE-marked instrument capable of measuring less than 50ng of protein and thus meeting DoH requirements

[hastings] 24/1/2017 07:45

Positive forward picture with FinnCap unchanged on forecasts and 20p target price.Another acquisition this year looks highly likely.

[basem1] 24/1/2017 07:32

Impressive results, read very well. Further contributions from Astles in the 2nd half and more acquisitions to follow. Glad I'm in here, let's hope we can move the smallish overhang there seems to be at present.

[rivaldo] 19/1/2017 14:03

RNS - the shareholder list here gets even more ridiculously heavyweight, with Oryx buying almost another 3.9m shares and increasing to 8.35m, or 9.4%:

[rivaldo] 19/1/2017 12:16

Synbiosis news:



"Tuesday 17th January 2017

Produlab Pharma uses ProcScan and SynStats to rapidly generate accurate, traceable data on antibiotic potency

Cambridge, UK: Synbiosis, a long-established, expert manufacturer of automated microbiological systems, ispleased to announce its ProcScan inhibition zone measurement system is being used together with its SynStats statistical analysis software at specialist Dutch veterinary pharmaceutical firm, Produlab Pharma to accurately and reproducibly assess the quality of veterinary antibiotics.

Microbiologists at Produlab Pharma are using the ProcScan automated system to generate images of inhibition zones around antibiotics on large (240 mm x 240 mm) antibiotic susceptibility testing plates. The images are scanned directly into software, which automatically measures zone sizes and these values are transferred into SynStats statistical software. This rapidly analyses the results to provide standard curve and potency data. Using ProcScan in combination with SynStats is helping microbiologists at Produlab Pharma to precisely assess the efficacy of existing and re-engineered antibiotics to treat diseases such as mastitis in cattle.

Dave van Reusel, Microbiologist at Produlab Pharma commented: “We used to measure inhibition zones manually with callipers and then record the results on the computer. It would take us 30 minutes to analyse one plate and after this we had no image of our plates to refer to so there was no proof of our results to look at later.”

Dave added: “We chose the ProcScan because it is the only system that can image large antibiotic susceptibility testing plates and measure inhibition zones in a 6 x 6 grid. Before we had the ProcScan, it would require hours to analyse a run of 20-30 assay plates, now it takes a fraction of the time and we can record raw plate images to provide evidence for clients or regulators to assess when they need to.”

“Data integrity is currently a hot issue across the pharmaceutical industry,” stated Kate George, Senior Divisional Manager at Synbiosis, “scientists at Produlab Pharma are demonstrating that ProcScan and SynStats is a must have combination for quality assurance laboratories where generating accurate, consistent and more importantly, archived raw and analysed data of any antibiotics’ potency are critical requirements.”

[rivaldo] 17/1/2017 12:38

News:



"Thursday 12th January 2017

New GeneSys image capture software now available to download

Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is delighted to announce its GeneSys software has been upgraded to include an icon of pre-set optimised “stain-free” protein gel imaging conditions. This simple to use software, available to download free of charge to existing users of specified Syngene imaging systems, will save set-up time and ensure accurate stain-free protein gel images every time.....

etc"

[rivaldo] 16/1/2017 09:55

Greyingsurfer, hastings and noble3r are correct - notice that the Fund's shareholding has increased by 1.15m shares, it's simply that the placing has diluted their overall interest.

SDI is very volatile and illiquid due to its huge ownership of shares by blue chip institutions, and the MMs adjust the price accordingly. Only £6k has been traded today!

[pj 1] 16/1/2017 09:53

The previous dips in July, November and December proved excellent add points

[basem1] 16/1/2017 09:48

Looking very weak now ?

[noble3r] 12/1/2017 16:44

Greyingsurfer, number of shares prior to triggering transaction - 7706430, resulting situation after trigger 8860277. This is clearly an increase / purchase of shares but still a tiny dilution after placing.

[greyingsurfer] 12/1/2017 14:59

OK, makes sense thanks

[hastings] 12/1/2017 13:43

Greyingsurfer, I'm pretty sure they picked up more in the placing, but overall holding has been reduced through dilution.Business Growth Fund picked the larger chunks up as did Harwood Capital I believe.

[greyingsurfer] 12/1/2017 12:49

Are you sure? The RNS says they've reduced from over 12 to under 10%

[rivaldo] 12/1/2017 10:03

RNS - Octopus Investments have increased their holding by just over 1.15m shares. They now hold 8.86m shares, or 9.97%:

[shanklin] 11/1/2017 14:31

Oh ok, I could not find it on their web-site or in an RNS but that sounds pretty definitive.

Thank you

[hastings] 11/1/2017 13:56

I have a visit planned to coincide with the interims for a write up, so unless that date is changed between now and then, it should happen on that Tuesday.Hope that helps.H.

[shanklin] 11/1/2017 13:52

hastings

What is the source for 24-Jan please?

[hastings] 11/1/2017 12:51

Interims due on 24th.